MedPath

Impact of Regular Consumption of Grapes on Eye Health in Singapore Older Adults

Not Applicable
Active, not recruiting
Conditions
Eye Health
Age-related Macular Degeneration
Interventions
Dietary Supplement: Freeze-dried table grape powder
Dietary Supplement: Placebo of the table grape powder
Registration Number
NCT05064865
Lead Sponsor
National University of Singapore
Brief Summary

Aging epidemics in Singapore are rapidly increasing and Age-related macular degeneration (AMD) prevalence is significantly associated with older age. This study aims to understand the effect of consuming freeze-dried table grape powder on AMD in an older population.

Detailed Description

This will be carried out through a 16-week double-blind, randomized, placebo-controlled trial of parallel study design. Thirty-eight men and women (aged between 60 and 85 years old inclusive) will recruited and assigned to an intervention or placebo group. The intervention group will consume 46 g/day of a freeze-dried table grape and the control group will consume the same amount of a placebo, table grape placebo powder. Measurements of 1) macular pigment optical density (MPOD), a clinical marker for eye health, 2) carotenoids status, 3) markers of oxidative stress, 4) markers of endothelial function, 5) body size and blood pressure, and 6) dietary assessment will be assessed over the 16-week study. This study will consist of 1 screening visit and 5 study visits in 4-week intervals to the Food Science and Technology Department, Occupational Health Clinic and National University Heart Centre.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
34
Inclusion Criteria
  • Male and female participants, aged between 60 and 85 years old inclusive
  • Able to give informed consent in English
Exclusion Criteria
  • Smokers
  • Allergy to grapes
  • Known eye diseases (macular degeneration, cataracts, retinopathy or glaucoma), blindness in at least one eye or have had eye surgery
  • Abnormal kidney and liver function
  • Taking eye medication and/or dietary supplements for the eyes for the past 3 months
  • Taking supplements containing carotenoids (e.g. Vitamin A, lutein, zeaxanthin) for the past 3 months
  • Currently on type 2 diabetic medication.
  • Currently on anti-hypertensive or cholesterol-lowering; unless this prescription has been ongoing for more than 3 years prior to study participation.
  • Currently on a specialized diet (e.g. vegetarian, vegan, weight loss diet, low fat diet)
  • Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider or 45ml of distilled spirit.
  • Significant change in weight (≥ 3 kg body weight) in the past 3 months
  • Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
  • Poor peripheral venous access based on past experiences with blood draw
  • Participating in another clinical study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Freeze-dried table grape powderFreeze-dried table grape powderThe intervention group will consume 46 g/day of a freeze-dried table grape powder.
Placebo grape powderPlacebo of the table grape powderThe control group will consume the same amount of a placebo with a similar taste to the table grape powder.
Primary Outcome Measures
NameTimeMethod
Change in skin carotenoid statusEvery four weeks (week 0, week 4, week 8, week 12, week 16)

Skin carotenoid status (a.u) measured using NuSkin II, resonance Raman spectroscopy

Change in blood carotenoid concentrationEvery eight weeks (week 0, week 8, week 16)

Blood carotenoid concentration to be quantified by HPLC

Change in macular pigment optical densityEvery four weeks (week 0, week 4, week 8, week 12, week 16)

Macular pigment optical density will be measured using macular pigment scanner

Secondary Outcome Measures
NameTimeMethod
Change in total triglycerideEvery eight weeks (week 0, week 8, week 16)

Total triglyceride (mmol/l)

change in waist circumferenceEvery four weeks (week 0, week 4, week 8, week 12, week 16)

Waist circumference (cm) measured using measuring tape

Change in body weightEvery four weeks (week 0, week 4, week 8, week 12, week 16)

Body weight (kg) measured using body scale

Change in the concentration of malondialdehyde in plasmaEvery eight weeks (week 0, week 8, week 16)

Malondialdehyde concentration

Change in the concentration of 8-iso-prostaglandin F2α in plasmaEvery eight weeks (week 0, week 8, week 16)

8-iso-prostaglandin F2α concentration

Change in high-density lipoprotein cholesterolEvery eight weeks (week 0, week 8, week 16)

High-density lipoprotein cholesterol (mmol/l)

Change in endothelial functionweek 0 and week 16

Endothelial functions are determined by the function of endothelial progenitor cells

Change in the concentration if Nitric Oxide in plasmaweek 0 and week 16

Nitric Oxide concentration

Change in total cholesterolEvery eight weeks (week 0, week 8, week 16)

Total cholesterol (mmol/l)

Change in flow mediate dilationweek 0 and week 16

Flow mediate dilation (%)

Change in blood glucose concentrationEvery eight weeks (week 0, week 8, week 16)

Blood glucose concentration (mmol/l)

Change in low-density lipoprotein cholesterolEvery eight weeks (week 0, week 8, week 16)

Low-density lipoprotein cholesterol (mmol/l)

Change in the concentration if Endothelin-1 in plasmaweek 0 and week 16

Endothelin-1 concentration

Change in BMIEvery four weeks (week 0, week 4, week 8, week 12, week 16)

Weight and height will be combined to report BMI in kg/m\^2

Change in blood pressureEvery four weeks (week 0, week 4, week 8, week 12, week 16)

Systolic and diastolic blood pressure (mmHg) measured using sphygmomanometer

Trial Locations

Locations (1)

National University of Singapore

🇸🇬

Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath